GlassScriptPhysician profile
Jessica Craddock
NPI 1154614469
$266,272.43
in general payments reported to CMS, 2019-2025
19 companies · $38K in 2025
The $38K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $26K · 2021: $25K · 2022: $26K · 2023: $46K · 2024: $51K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Consulting Fee: $8,533 · Travel and Lodging: $7,418 · Food and Beverage: $4,085.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,137.75 |
| Consulting Fee | $8,533.00 |
| Travel and Lodging | $7,417.88 |
| Food and Beverage | $4,085.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $153,615.76 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $70,071.19 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Tg Therapeutics, INC. | $20,363.69 | 2023-2025 | |
| Genentech USA, INC. | $14,508.45 | 2019-2024 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $6,453.54 | 2019-2024 | |
| Celgene Corporation | $633.35 | 2020-2025 | Zeposia |
| Alexion Pharmaceuticals, INC. | $276.39 | 2019-2024 | Ultomiris |
| Genzyme Corporation | $89.78 | 2019-2024 | |
| Amgen INC. | $43.80 | 2025 | Uplizna |
| Allergan, INC. | $37.66 | 2019-2020 | |
| Banner Life Sciences, LLC | $28.56 | 2023 | |
| Janssen Pharmaceuticals, INC | $28.33 | 2022 | |
| Mallinckrodt Hospital Products INC. | $25.80 | 2020 | |
| Merz Pharmaceuticals, LLC | $23.98 | 2023 | Xeomin |
| Astrazeneca Pharmaceuticals LP | $19.58 | 2023 | Evusheld |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $19.21 | 2023 | Vyvgart Hytrulo |
| Ipsen Biopharmaceuticals, INC | $18.68 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.68 | 2025 | Hyqvia |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Craddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.